Companies: 10,795·Total market cap: $144.5T
Anavex Life Sciences Corp.

Anavex Life Sciences Corp.

AVXLNASDAQHealthcare● Active
$2.56
$-0.02(-0.58%)
Market Cap$236776342
P/E Ratio—
52W High$13.99
52W Low$2.56
SEC Filings

Anavex Life Sciences Corp. (AVXL) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001314052 · AVXL · NASDAQ · as of Jun 8, 2026

Filing snapshot

584
Total Filings
8-K
Latest Form
2026-05-22
Most Recent
2006
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001314052 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2025-11-25
Fiscal Year End
Nov 25, 2025
Accession No.
0001731122-25-001596
Primary Document
e7052_10-k.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001314052 · Accession 0001731122-25-001596

Latest Key Filings

10-QQuarterly Report
FORM 10-Q
2026-02-09
View 10-Q on SEC
8-KCurrent Report
FORM 8-K
2026-05-22Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
FORM 8-K
2026-05-22
View
8-KCurrent Report
FORM 8-K
2026-05-15
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-05-14
View
NT 10-QNT 10-Q
FORM NT 10-Q
2026-05-11
View
8-KCurrent Report
FORM 8-K
2026-05-06
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-05-01
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-26
View
8-KCurrent Report
FORM 8-K
2026-03-25
View
8-KCurrent Report
FORM 8-K
2026-02-25
View
10-QQuarterly Report
FORM 10-Q
2026-02-09
View
8-KCurrent Report
FORM 8-K
2026-02-09
View
10-KAnnual Report
FORM 10-K
2025-11-25
View
8-KCurrent Report
FORM 8-K
2025-11-25
View
8-KCurrent Report
FORM 8-K
2025-11-14
View
10-QQuarterly Report
FORM 10-Q
2025-08-12
View
Showing 1–15 of 414 filingsForm 4 / 144 hidden· 584 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001314052  |  Exchange: NASDAQ · Healthcare

Anavex Life Sciences Corp. (NASDAQ: AVXL) has submitted 584 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2006. As a Healthcare sector company with CIK 0001314052, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Anavex Life Sciences Corp.'s most comprehensive regulatory disclosure. The most recent Anavex Life Sciences Corp. 10-K was filed on 2025-11-25 for fiscal year ending 2025. Historical AVXL 10-K annual reports are available from 2005 through 2025.

Investors researching Anavex Life Sciences Corp. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
ERAS SEC Filings →MLTX SEC Filings →ABSI SEC Filings →MBX SEC Filings →MGTX SEC Filings →ATXS SEC Filings →ARVN SEC Filings →VALN SEC Filings →
→ AVXL Financials→ AVXL Earnings→ AVXL Insider Trades

Frequently Asked Questions

AVXL SEC Filings · 8 questions

Anavex Life Sciences Corp. (AVXL) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 584 filings and access original documents at no cost. Anavex Life Sciences Corp.'s CIK is 0001314052.

AVXL SEC filingsAnavex Life Sciences Corp. SEC documentsfind AVXL 10-K